PTC Therapeutics
PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield, NJ 07080
Phone: (908) 222-7000Website: https://www.ptcbio.com/
Latest news
- PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients
1 October 2024 - PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
17 May 2023 - PTC Therapeutics Receives FDA Approval for the Expansion of the Emflaza (deflazacort) Labeling to Include Patients 2-5 Years of Age
7 June 2019 - PTC Therapeutics Completes Acquisition of Emflaza for the Treatment of Duchenne Muscular Dystrophy in the U.S.
20 April 2017 - FDA Approves Emflaza (deflazacort) to treat Duchenne Muscular Dystrophy
9 February 2017 - FDA Accepts Marathon Pharmaceuticals’ NDA for Deflazacort for the Treatment of Duchenne Muscular Dystrophy
10 August 2016 - Marathon Pharmaceuticals Announces Submission of Deflazacort New Drug Application to the FDA
14 June 2016 - Marathon Pharmaceuticals to Begin NDA Process for Deflazacort as a Potential Treatment for Patients with Duchenne Muscular Dystrophy
5 August 2015 - Marathon Pharmaceuticals Receives FDA Fast Track Designation for Deflazacort as a Potential Treatment for Duchenne Muscular Dystrophy
19 January 2015
Drugs Associated with PTC Therapeutics, Inc.
PTC Therapeutics, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Emflaza
Generic name: deflazacort Drug class: glucocorticoids |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||